摘要
目的 观察紫杉醇酯质体联合顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应.方法 32例有可测量病灶,无法手术切除或术后复发、远处转移的晚期NSCLC患者均采用紫杉醇酯质体联合顺铂方案化疗,21d为一个周期.每化疗2个周期,对可测量病灶行CT或MRI检查以评价疗效,并记录化疗期间毒副反应发生情况.结果 总有效率为40.6%,其中初治者有效率为47.1%,复治者有效率为33.3%,2者比较差异有统计学意义;病理类型中腺癌有效率为42.1%,鳞癌有效率为41.6%,二者比较差异无统计学意义;患者的毒副反应主要为骨髓抑制、胃肠道反应和周围神经毒性,多为Ⅰ~Ⅱ级.结论 紫杉醇酯质体联合顺铂治疗晚期NSCLC疗效确切,毒副反应小,患者耐受性好,值得临床广泛推广应用.
Objective To observe the clinical effects and toxic and side effects of paelitaxel liposome plus cisplatin for treating advanced non-small cell lung cancer (NSCLC).Methods Thirty-two advanced NSCLC patients with measurable focus,postoperative recurrence and distal metastasis or not capable of surgical excision were all given paclitaxel liposome plus cisplatin chemotherapy,with 21 days as one course of treatment.CT or MRI were performed on measurable focuses to evaluate the therapeutic effects every 2 cycles of chemotherapy,and the incidence of toxic and side effects during chemotherapy was recorded.Results The total effectiveness rate was 40.6 %,among whom the effective rates of initially-treated and retreatment patients were respectively 47.1% and 33.3 %.In the effectiveness rates between the two groups,the difference showed statistical significance.In terms of pathological types,the effectiveness rates of adenocarcinoma and squamous carcinoma were 42.1% and 41.6% respectively.In the effectiveness rates between the two groups,the difference showed no statistical significance.The toxic and side effects of patients mainly were myelosuppression,gastrointestinal reactions and peripheral neuropathy,mostly at grades Ⅰ-Ⅱ.Conclusion In the treatment of NSCLC,the therapeutic effects of paclitaxel liposome plus cisplatin are specific,with less toxic and side effects,and can be tolerated well,so it is worthy of extensive popularization and application in clinical practice.
出处
《实用临床医药杂志》
CAS
2013年第14期59-61,共3页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(11321001)
关键词
紫杉醇酯质体
顺铂
非小细胞肺癌
毒副反应
paclitaxel liposome
cisplatin
non-small cell lung cancer
toxic and side effects